Skip to main content

Table 1 HbA1c (%) variability in the pooled empagliflozin and placebo arms separately, at week 28 and 52

From: Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial

 

Number of patients

Standard deviation

Median (IQR)

Coefficient of variation

Median (IQR)

Range

Median (IQR)

Week 28

Week 52

Week 28

Week 52

Week 28

Week 52

Week 28

Week 52

Placebo

2171

2112

0.3 (0.1, 0.6)

0.4 (0.3, 0.7)

3.9 (1.9, 6.8)

5.4 (3.6, 8.2)

0.4 (0.2, 0.8)

1.0 (0.6, 1.4)

Empagliflozin

4400

4304

0.2 (0.1, 0.4)

0.3 (0.2, 0.5)

3.1 (1.2, 5.8)

4.4 (3.0, 6.6)

0.3 (0.1, 0.6)

0.7 (0.5, 1.1)

p-value*

  

 < 0.0001

 < 0.0001

 < 0.0001

 < 0.0001

 < 0.0001

 < 0.0001

  1. p-value for difference between placebo and pooled empagliflozin arms. Only patients with at least two post-baseline HbA1c measurements up until week 28 or 52, respectively, are included
  2. * From Wilcoxon test
  3. IQR Inter-quartile-range